Business Wire

Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile


Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today presented data from the Phase 3 ReSTORE clinical trial of rezafungin in the treatment of candidemia and/or invasive candidiasis at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data, presented in a late-breaking poster, showed non-inferiority for rezafungin dosed once-weekly compared to caspofungin, the current standard of care, dosed once-daily, for both primary endpoints.1

This press release features multimedia. View the full release here:

Results from ReSTORE showed the primary endpoints were met with:1

  • 23.7% all-cause mortality on day 30 for rezafungin compared to 21.3% for caspofungin (difference, 2.4; 95% CI for risk difference -9.7 to 14.4*)
  • global cure on day 14 of 59.1% for rezafungin and 60.6% for caspofungin (difference, -1.1; 95% CI for risk difference -14.9* to 12.7)
    • *To meet the pre-specified limit of non-inferiority, the upper (for all-cause mortality) and lower (for global cure) 95% confidence limits for the difference between arms must be within 20%. Both endpoints met the pre-specified 20% limit, establishing non-inferiority.

Further data from the ReSTORE trial demonstrated high rates of early mycological efficacy with rezafungin:1

  • negative blood culture at 24 hours was 53.7% for rezafungin versus 46.2% for caspofungin and 74.2% versus 64.1% at 48 hours
  • median time to negative blood culture was 23.9 hours for rezafungin versus 27.0 hours for caspofungin (p=0.175)

Additional data from an oral late-breaking presentation at ECCMID from an integrated analysis of the Phase 2 STRIVE and Phase 3 ReSTORE data of rezafungin in the treatment of candidemia and/or invasive candidiasis, supports the analysis of ReSTORE2:

  • 18.7% all-cause mortality on day 30 for rezafungin compared to 19.4% for caspofungin (weighted mortality difference, -1.5%; 95% CI: -10.7 to 7.7, stratified analysis by study)
  • percentage of subjects with negative blood culture at 24 hours was 60.0% for rezafungin versus 49.1% for caspofungin and 77.7% versus 63.5% at 48 hours
  • median time to negative blood culture was 22.3 hours for rezafungin versus 26.3 hours for caspofungin (p=0.0051)

Both the STRIVE and ReSTORE trials demonstrated similar tolerability outcomes for rezafungin and caspofungin and did not reveal any concerning trends in TEAEs or SAEs.1,2

Further data presented at ECCMID assessing the pharmacokinetics of drug interactions between rezafungin and anticancer agents venetoclax or ibrutinib demonstrated that in subjects receiving multiple drug interventions, rezafungin can be given with no dose adjustments due to pharmacokinetics. 3

“The results of both the STRIVE and ReSTORE trials, as well as the pharmacokinetics data, provide clear evidence of the potential impact that rezafungin could have for patients fighting serious and hard to treat invasive Candida infections,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We look forward to submitting our NDA to the FDA in mid-2022 and subsequent ex-US submissions, and to making a difference in the lives of patients.”

Oliver Cornely investigator in the ReSTORE trial and Professor of Internal Medicine at the University of Cologne, Germany, added, “As the mortality rate for patients with invasive candidiasis remains high there is a real unmet need for new treatment options to address this serious disease. Rezafungin could be the first new treatment option for patients with candidemia or invasive candidiasis for over 10 years.”

Brian Sheehan, Ph.D., Chief Scientific Officer at Mundipharma, commented, “We are extremely pleased that these data presented today may help pave the way for once-weekly rezafungin to help critically ill patients with invasive Candida infections. The results from these important trials provide initial evidence that the unique pharmacokinetic/pharmacodynamic profile of rezafungin may lead to quicker fungal clearance for patients with Candida infections.”

Cidara has partnered with Mundipharma who has commercial rights to rezafungin outside the U.S. and Japan.


ReSTORE (NCT03667690) is a global, multicentre, randomized, double-blind, controlled Phase 3 efficacy and safety study of once weekly rezafungin injections versus an active comparator regimen of caspofungin followed by optional oral fluconazole step-down therapy in subjects with candidemia and/or invasive candidiasis. ReSTORE evaluated one 400 milligram (mg) dose of rezafungin in week 1 followed by 200 mg of rezafungin dosed once-weekly for up to four weeks. The treatment arm was compared to approved daily dosing of caspofungin in a 1:1 randomization (n=98 in each arm).1 It completed enrollment with 199 patients diagnosed with candidemia and/or invasive candidiasis in 66 clinical sites across 18 countries. Study sites in China are still recruiting patients for submission of rezafungin to the Center for Drug Evaluation in China.


STRIVE (NCT02734862) was a global, multicenter, randomized, double-blind Phase 2 study of the safety, tolerability, and efficacy of intravenous rezafungin (n=138)2 versus intravenous caspofungin (n=69)2 followed by optional oral fluconazole step-down in the treatment of subjects with candidemia and/or invasive candidiasis. It was completed with 207 participants enrolled in 63 clinical sites across 10 countries.

About Pharmacokinetics Study

An open-label study of 16 male and 16 female healthy volunteers assessed drug-drug interactions between rezafungin and anticancer agents 280mg ibrutinib or 50mg venetoclax (females only). The two anticancer agents were each given along and with IV rezafungin (400mg followed by once-weekly 200mg).3

About Invasive Candidiasis

Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite available treatments, the mortality rate for patients with invasive candidiasis remains as high as 40%.4 IC is characterized as a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues, known as candidemia and deep-seated tissue candidiasis.5

About Rezafungin

Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia. The structure and properties of rezafungin are specifically designed to enhance its efficacy and safety potential for patients. Cidara has completed a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial).4

Cidara is also currently conducting a second Phase 3 clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

Rezafungin has been designated a Qualified Infectious Disease Product (QIDP) with Fast Track status by the FDA and has been granted Orphan Drug Designation for its use in the treatment of invasive candidiasis in both the U.S. and EU.6,7 In addition, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted rezafungin Promising Innovative Medicine (PIM) designation for the treatment of invasive candidiasis.8

About Cidara Therapeutics

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit

About Mundipharma

Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.

Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas. Our guiding principles, centered around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to whether an unmet medical need exists for rezafungin; whether rezafungin will be approved for marketing in the US, the UK and other countries; the potential timing of marketing authorisation submissions; the likelihood that rezafungin, if approved for treatment of fungal infections, will be prescribed by physicians or approved for reimbursement, and whether rezafungin can be proven safe or effective in prevention of fungal infections in patients receiving oral anticancer agents. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s pre-clinical or clinical trials, delays in action by regulatory authorities due to limitations on inspections and other COVID-19-related effects, and impacts of the COVID-19 pandemic or other obstacles on the enrollment of patients or other aspects of rezafungin development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.


1 Thompson, G.R. et al, ReSTORE: Efficacy and Safety Results of the Phase 3, Noninferiority Trial of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis, Abstract presented at ECCMID 2022

2 Soriano, A et al, Patient-level Meta-Analysis of Efficacy and Safety from STRIVE and ReSTORE: Randomized, Double-blinded, Multicenter Phase 2 and Phase 3 Trials of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis, Abstract presented at ECCMID 2022

3 Flanagan, S et al, Venetoclax and Ibrutinib Pharmacokinetics Unaltered when Coadministered with Rezafungin, Abstract presented at ECCMID 2022

4 Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015; 373:1445-1456.

5 Cortes JA, Corrales IF. Invasive Candidiasis: Epidemiology and Risk Factors. November 2018. Available at Last accessed March 2022

6 U.S. Food & Drug Administration. Search Orphan Drug Designations and Approvals. Available at: 507215. Last accessed March 2022

7 European Commission. Community Register of orphan medicinal products. Available at: Last accessed March 2022

8 PIM designation guidance. Available at: Last accessed March 2022

To view this piece of content from, please give your consent at the top of this page.

Contact information

Brian Ritchie, LifeSci Advisors
(212) 915-2578

Patrick Bursey, LifeSci Communications
(203) 430-9545

Jan Milton-Edwards, Mundipharma
+44 7341 739 984

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Maxion Wheels and Challenge4 Set New Guinness World Record for High-Altitude Drive in an All-electric Vehicle23.5.2022 19:37:00 EEST | Press release

Maxion Wheels, the world’s largest wheel manufacturer, and long-distance driver Rainer Zietlow and the Challenge4 team, successfully set a new Guinness World Record for driving to the highest altitude in the all-electric VW ID.4 GTX. Equipped with Maxion’s robust, lightweight and sustainable steel wheels, the team drove to the top of Bolivia’s Uturuncu volcano, 5,816 meters above sea level, breaking the previous record set in 2020 by approx. 45 meters of altitude. This press release features multimedia. View the full release here: New highest altitude by an electric vehicle Guinness World Record is set by Maxion Wheels and Challenge4 with the ascent of a VW ID.4 GTX riding on Maxion steel wheels to the top of Bolivia's Uturuncu volcano. (Photo: Business Wire) Guinness World Records today presented Challenge4 with the official certificate during a press conference at the German Embassy in La Paz, Bolivia. “This world record under

Innovative IoT Modem Card From Thales Makes It Easier to Build a 5G World of Trust23.5.2022 18:15:00 EEST | Press release

Thales announces the new Cinterion® MV32 modem card that makes it quicker and easier for manufacturers to build and maintain resilient, high-performance 5G devices that will transform everyday life in the years ahead. Harnessing the full potential of 5G Mobile Broadband connectivity, the new modem card is designed to be at the heart of a wide array of demanding IoT (Internet of Things) use cases, such as securely connecting enterprises, remote patient care and intelligent monitoring of renewable energy generation. This press release features multimedia. View the full release here: Thales 5G IoT (Graphic: Thales) Effortlessly connecting 5G networks and next-gen IoT devices The 5G roll-out will not only bring unprecedented mobile broadband speed to billions of people worldwide. It also offers an extraordinary leap in the sheer number of devices that cellular networks can support. Connectivity will be enabled for billions more mach

Fabasoft Approve is now an autonomous limited liability company23.5.2022 17:05:00 EEST | Press release

Fabasoft Approve, the product for managing technical data and documents launched by software manufacturer Fabasoft and employed successfully in industry since 2019, became an independent company on April 27, 2022. Entrepreneur Andreas Dangl will assume the management of the new digitalization services company. As a defining leader in the Fabasoft Group, Dangl was responsible for the development of Fabasoft Cloud technology and was both the idea generator as well as the principal architect of software products including Fabasoft Approve. He is now pooling his expertise in the corporation based in Linz (Austria) with the express intention of re-imagining the digital world in mechanical and plant engineering and rendering it simpler to navigate. “Fabasoft Approve GmbH provides the perfect framework for meeting the needs of our industrial customers in an even more focused way. We have exciting times ahead of us, in which my team and I, together with our clients, will tap the innovative pot

“PUMA and the Land of Games”: New Virtual Place on Roblox for PUMA Fans to Connect and Compete23.5.2022 17:00:00 EEST | Press release

PUMA in partnership with Wonder Works studio launches a vibrant and immersive sports-based experience on Roblox, a global online platform connecting millions of people through shared experiences. PUMA and the Land of Games experience features Roblox newest Layered Clothing technology, where players can customize their characters with hyperrealistic clothing that fits any avatar body type to wear PUMA from head to toe. As they explore the experience, fans will unlock new zones and additional PUMA sportswear pieces. This press release features multimedia. View the full release here: PUMA in partnership with Wonder Works studio launches a vibrant and immersive sports-based experience on Roblox, a global online platform connecting millions of people through shared experiences. (Photo: Business Wire) “PUMA and the Land of Games” offers the global Roblox community to bring out their inner athlete through sports mini games and training

Fabrice Tocco, Dawex co-CEO, Speaking at the World Economic Forum Annual Meeting in Davos about Data Ecosystems to Respond to Competitiveness and Economic Sovereignty Challenges23.5.2022 16:40:00 EEST | Press release

Dawex, the leading technology company for data exchange, data marketplace and data hub, announced today that co-CEO Fabrice Tocco will be speaking at the World Economic Forum Annual Meeting in Davos, and will share his vision on creating new data exchange ecosystems to respond to environmental and economic challenges. This press release features multimedia. View the full release here: Live Session at Davos (Photo: Dawex) “Strengthening Trust in Public-Private Data Exchanges” Tuesday, May 24 at 13:30 CET Data ecosystems have become a fundamental component of business competitiveness and economic sovereignty. In today’s economy where data has become a product of unlimited potential, with its own value, and a source of new revenue streams, Dawex technology allows organizations to create new ecosystems around data exchange platforms that meet regulatory requirements and address traceability and security challenges. About Dawex In to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom